Key statistics dashboard for Allogene Therapeutics, Inc. (ALLO). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy.
Stock Data
| Price | $1.69 |
| Market Cap | $583M |
| Enterprise Value | $615.0M |
| Beta | 0.54 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -2.57 |
| Price / Book | 1.30 |
| P/S | 127.95 |
| EV/EBITDA | -4.03 |
| EV/Sales | 132.55 |
| EV/FCF | -5.99 |
| P/FCF | -5.79 |
| Earnings Yield | -29.77% |
| FCF Yield | -17.59% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | -699.35% |
| EBIT Margin | -3538.66% |
| EBITDA Margin | -3287.20% |
| Operating Margin | -3886.14% |
| Net Margin | -3566.68% |
| Return on Equity | -50.04% |
| Return on Assets | -30.08% |
| Return on Invested Capital | -34.79% |
| Return on Capital Employed | -34.79% |
Financial Health
| Current Ratio | 10.72 |
| Quick Ratio | 10.72 |
| Cash Ratio | 1.22 |
| Debt / Equity | 0.16 |
| Debt / Assets | 12.79% |
| Net Debt / EBITDA | -0.21 |
| Interest Coverage | -138.71 |
Per-Share Data
| Revenue per share | 0.01 |
| Book Value per share | 1.33 |
| Cash per share | 1.01 |
| FCF per share | -0.31 |
| Tangible Book Value per share | 1.33 |
| Dividend per share | 0.00 |
Related companies: ACHV · AVIR · CABA · CRBU · EDIT · HUMA · IMMP
Explore sector: Healthcare · Biotechnology
More sections of ALLO: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks